ClinicalTrials.gg
CompletedNCT00277095ProACTUpdated May 31, 2018Results posted

ProACT Therapy for the Treatment of Stress Urinary Incontinence in Males

An interventional study of ProACT (Adjustable Continence Therapy) in Urinary Incontinence, sponsored by Uromedica. Completed at 10 sites in 3 countries. Open to male participants aged 45 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-05-31.

Sponsored by Uromedica · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
123
Allocation
Not applicable
Ages
45 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 293 studies in Urinary Incontinence with a site in United States — 33 open to participants now, 47 under way, 3 of them phase 3. Urinary Incontinence · United States.

Enrollment
92nd of 249
123 · median 75
Started
2005
with 11 others
No phase
144 of 293
21 open now
Registered
26th of 293
by date

Among the 293 studies in Urinary Incontinence with a site in United States, this one is the 92nd largest by enrollment of the 249 interventional ones that give a count, is one of 12 that started in 2005, is one of 144 with no phase, and was the 26th registered.

Urinary Incontinence

988 studies on the registry are indexed under Urinary Incontinence; 184 are open to participants now.

Browse Urinary Incontinence studies →

Open to participants now

33 of the 293 studies in Urinary Incontinence with a site in United States are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 113 Urinary Incontinence studies recruiting now, 63 (56%) set no upper age limit and 35 (31%) stop at 75 or younger; 15 take children under 18; 28 take healthy volunteers.

This study: 45 Years and older · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 293 studies in Urinary Incontinence with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the safety and effectiveness of a minimally invasive surgical procedure in up to 109 male patients. The ProACT device is designed to treat men who have stress urinary incontinence arising from intrinsic sphincter deficiency following an operation performed on the prostate for cancer or for benign prostatic hyperplasia. Two adjustable balloons (one on each side of the urethra) are implanted to treat urinary stress incontinence.

The results will be analyzed to demonstrate the effects of the device as well as its associated risks. Therapeutic success will be based on whether patients demonstrate at least a 50% reduction in pad weight at 18 months follow-up compared to the pad weight results at baseline.

Read the detailed description

The study is a prospective, non-randomized multi-center investigation. Multiple measurements using 24 hour pad weight and pad count, validated questionnaires, voiding diaries will be used to evaluate the achievement of the study objectives. Subjects will be followed for a minimum of 18 months following implantation. Subjects will be requested to continue annual follow-ups through the FDA approval.

The purpose of the study is to evaluate the safety and effectiveness of a minimally invasive surgical procedure in up to 109 male patients. The ProACT device is designed to treat men who have stress urinary incontinence arising from intrinsic sphincter deficiency following an operation performed on the prostate for cancer or for benign prostatic hyperplasia. Two adjustable balloons (one on each side of the urethra) are implanted to treat urinary stress incontinence.

The results will be analyzed to demonstrate the effects of the device as well as its associated risks. Therapeutic success will be based on whether patients demonstrate at least a 50% reduction in pad weight at 18 months follow-up compared to the pad weight results at baseline.

03

Conditions studied

  • Urinary Incontinence

Browse trials for

Keywords

  • Urinary Incontinence
04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Undergone either a radical prostatectomy, transurethral resection of the prostate or other prostate surgery at least 12 months prior without radiation therapy
  • Demonstrate primary stress urinary incontinence
  • Male subjects at least 45 years of age
  • Willing and able to undergo surgical implantation of the ProACT devices
  • Willing and able to comply with the follow-up requirements
  • Willing and able to forego any other surgical urinary incontinence treatments while participating in the study
  • Willing and able to sign the
  • Positive 24 hour pad weight tests (greater than or equal to 8 gram pad weight increase demonstrated in two 24-hour pad weight tests)
  • Experiences at least 3 incontinence episodes per day during two baseline voiding diaries.
  • Negative Urine culture
  • No recurrent stricture at the anastamosis
  • No known urogenital other than previously treated prostate cancer
  • Physician determines subject to be suitable surgical candidate

Exclusion criteria

Exclusion Criteria:

  • Primarily Urge incontinence
  • Detrusor instability or over-activity
  • Residual volume greater that 100 ml or greater than 25% of the total bladder capacity after voiding.
  • Subject has/had or is suspected of having bladder cancer
  • History of recurrent bladder stones
  • Neurogenic bladder that is atonic or has detrusor sphincter dyssynergia
  • Known hemophilia or a bleeding disorder
  • Abnormal PSA (Prostate Specific Antigen), according to sites laboratory standards, unless further investigation confirms no underlying prostate .
  • Known sever contrast solution allergy
  • Has a genitourinary mechanical prosthesis other than previous sling procedure (e.g., Artificial Urinary sphincter, implantable penile prosthesis)
  • Has a urethral stricture that prevents passage of an 18 F cystoscope or has had more than one urethrotomy
  • Undergone bulking procedure within 6 months of the baseline assessment
  • Subject is currently enrolled or plans to enroll in another device or drug clinical trial.
  • Subject is currently using an indwelling catheter or condom catheter for treatment of incontinence and is not willing to discontinue use at least 4 weeks prior to baseline assessment.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
123 participants (actual)

Study arms

  • Experimental
    ProACT (Adjustable Continence Therapy)

    Implantation with ProACT (Adjustable Continence Therapy), Single Arm

    Device: ProACT (Adjustable Continence Therapy)

Interventions

  • DeviceProACT (Adjustable Continence Therapy)

    Implantable device to reduce urinary stress incontinence

    Also known as: ProACT,Adjustable Incontinence therapy for Males

06

What researchers measure

Primary outcomes

  1. Primary Efficacy: Demonstrate the Efficacy of the ProACT Device in Reducing Incontinence as Measured by the 24-hour Pad Weight at 18 Months Compared to Baseline. A Subject is a Success if he Demonstrates a 50% Reduction.

    The percentage of participants with 50% reduction in pad weight.

    Time frame: 18 month follow-up

07

Results

Posted Feb 3, 2016

Participant flow

Participant flow — Overall Study
MilestoneImplantable Device
Started124
Completed103
Not completed21
Withdrew: Death2
Withdrew: Explanted7
Withdrew: Lost to follow-up2
Withdrew: Missed follow-up9
Withdrew: Physician decision1

Outcome measures

PrimaryPrimary Efficacy: Demonstrate the Efficacy of the ProACT Device in Reducing Incontinence as Measured by the 24-hour Pad Weight at 18 Months Compared to Baseline. A Subject is a Success if he Demonstrates a 50% Reduction.

The percentage of participants with 50% reduction in pad weight.

Time frame:
18 month follow-up
Reported as:
Number · percentage of patients
Primary Efficacy: Demonstrate the Efficacy of the ProACT Device in Reducing Incontinence as Measured by the 24-hour Pad Weight at 18 Months Compared to Baseline. A Subject is a Success if he Demonstrates a 50% Reduction.
percentage of patientsUrine Loss ( in Grams)
Primary Efficacy: Demonstrate the Efficacy of the ProACT Device in Reducing Incontinence as Measured by the 24-hour Pad Weight at 18 Months Compared to Baseline. A Subject is a Success if he Demonstrates a 50% Reduction.60.6 (50 to 70)

Adverse events

Collected over 18 Months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ProACT—4/124 (3.2%)112/124 (90.3%)
Most frequent serious events
Most frequent serious events
EventProACT
CVAVascular disorders1/124
Low Heart RateCardiac disorders1/124
Ulcerative ColitisGastrointestinal disorders1/124
SepsisInfections and infestations1/124
Most frequent other events
Showing 10 of 17
Most frequent other events
EventProACT
Other GenitourinaryRenal and urinary disorders46/124
Other Non GenitourinaryGeneral disorders40/124
Pain GenitourinaryRenal and urinary disorders35/124
Worsening IncontinenceRenal and urinary disorders35/124
Balloon MigrationInvestigations21/124
Infection, Urinary TractRenal and urinary disorders20/124
RetentionRenal and urinary disorders18/124
Perforation During ImplantInvestigations17/124
DermotologicSkin and subcutaneous tissue disorders13/124
Gastrointestinal ConditionGastrointestinal disorders13/124

Baseline characteristics

Age, Continuous
Age, Continuous(years)ProACT
Mean69.7 ± 7.9
Sex: Female, Male
Sex: Female, Male(Participants)ProACT
Female0
Male124
Region of Enrollment
Region of Enrollment(participants)ProACT
United States68
Canada44
New Zealand12
08

Study locations

10 sites
  • University of Arizona
    Tucson, Arizona 85724, United States
  • Kaiser Permanente-Los Angeles
    Los Angeles, California 90027, United States
  • The Pelvic Clinic
    Pembroke Pines, Florida 33028, United States
  • Indian River Urology
    Vero Beach, Florida 32960, United States
  • Urological Surgeons
    Kankakee, Illinois 60901, United States
  • Metro Urology
    Saint Paul, Minnesota 55102, United States
  • Kansas City Urology Care
    Kansas City, Missouri 64123, United States
  • Can-Med Clinical Research Inc.
    Victoria, British Columbia V8T5G1, Canada
  • CHUS-Fleurimont
    Fleurimont, Quebec J1H5N4, Canada
  • Urology Bay of Plenty (formerly Promed Urology)
    Tauranga, New Zealand
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2005, a primary completion of Feb 2009 and a completion of Dec 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2016, 7 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2006
First posted
Jan 13, 2006
Start
Aug 2005
Primary completionActual
Feb 2009
CompletionActual
Dec 2017
Results first posted
Feb 3, 2016
Last update
May 31, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 31, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00277095
Lead sponsor
Uromedica
Responsible party
Sponsor
First posted
Jan 13, 2006
Start date
Aug 2005
Primary completion
Feb 2009
Completion
Dec 2017
Results posted
Feb 3, 2016
Last update
May 31, 2018

Study contacts

Tim Cook, Ph.D
study director · Uromedica, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion